ZGN-1061

In today's world, ZGN-1061 has become a topic of great importance and interest. Since its emergence, ZGN-1061 has captured the attention of millions of people around the world, generating debates, discussions and, in many cases, concrete actions. Its impact has transcended borders, cultures and generations, becoming a focal point of attention for experts, researchers, professionals and the general public. In this article, we will analyze various aspects related to ZGN-1061, exploring its origins, evolution, implications and possible future scenarios. Throughout these pages, we will unravel the mysteries surrounding ZGN-1061, breaking down its importance and relevance in the current context, providing a comprehensive and updated vision on this topic that concerns us so much.

ZGN-1061
Names
Preferred IUPAC name
-1-oxaspirooctan-6-yl] 3-(2-morpholin-4-ylethyl)azetidine-1-carboxylate
Other names
ZGN-1061, Aclimostat
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
DrugBank
UNII
  • InChI=1S/C26H42N2O6/c1-18(2)5-6-21-25(3,34-21)23-22(30-4)20(7-9-26(23)17-32-26)33-24(29)28-15-19(16-28)8-10-27-11-13-31-14-12-27/h5,19-23H,6-17H2,1-4H3/t20-,21-,22-,23-,25+,26+/m1/s1
    Key: QJWJPMLDQYEPPW-AUKZVGPFSA-N
  • CC(=CC1(O1)(C)2((CC23CO3)OC(=O)N4CC(C4)CCN5CCOCC5)OC)C
Properties
C26H42N2O6
Molar mass 478.630 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C , 100 kPa).

ZGN-1061 is an experimental drug that was developed by Zafgen for treatment of obesity and type 2 diabetes. It has a similar mechanism of action as the discontinued drug Beloranib but was considered safer; however, its development was also halted because of safety concerns.[1][2][3]

References

  1. ^ Christoffersen, Berit Østergaard; Sanchez-Delgado, Guillermo; John, Linu Mary; Ryan, Donna H.; Raun, Kirsten; Ravussin, Eric (April 2022). "Beyond appetite regulation: Targeting energy expenditure, fat oxidation, and lean mass preservation for sustainable weight loss". Obesity. 30 (4): 841–857. doi:10.1002/oby.23374. ISSN 1930-7381. PMC 9310705. PMID 35333444.
  2. ^ Wentworth, John M.; Colman, Peter G. (July 2020). "The methionine aminopeptidase 2 inhibitor ZGN-1061 improves glucose control and weight in overweight and obese individuals with type 2 diabetes: A randomized, placebo-controlled trial". Diabetes, Obesity and Metabolism. 22 (7): 1215–1219. doi:10.1111/dom.14009. hdl:11343/275507. PMID 32077231.
  3. ^ Goya Grocin, Andrea; Kallemeijn, Wouter W.; Tate, Edward W. (October 2021). "Targeting methionine aminopeptidase 2 in cancer, obesity, and autoimmunity". Trends in Pharmacological Sciences. 42 (10): 870–882. doi:10.1016/j.tips.2021.07.004. hdl:10044/1/102175. PMID 34446297.